Comparative Pharmacology
Head-to-head clinical analysis: ARIMIDEX versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIMIDEX versus TESLAC.
ARIMIDEX vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aromatase inhibitor; inhibits conversion of androgens to estrogens by binding to aromatase enzyme, reducing estrogen levels in tissues.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
1 mg orally once daily
250 mg intramuscularly three times per week
None Documented
None Documented
Terminal elimination half-life ~50 hours (range 30-60 hours); supports once-daily dosing.
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Primarily hepatic metabolism via N-dealkylation and glucuronidation; ~80% excreted in feces, <10% unchanged in urine.
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor